Home›Ophthalmology› Heavy silicone oil yields 80.1% reattachment in complex retinal detachment with inferior breaks
Heavy silicone oil yields 80.1% reattachment in complex retinal detachment with inferior breaksHeavy Silicone Oil Shows Promise for Complex Retinal Detachments
Survey of ophthalmologyPublished September 4, 2026Study authors: Dirani Karim, Kim Chaesik, Park Jeff, Gregory Andrew, Mir Ahsan, Abrams Gary, Hodges Brittany, Rajes…PubMed ↗DOI ↗Editorial oversight: Dr. Lars van Dijk, PhD · Surgical, Procedural & Diagnostic
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider heavy silicone oil for complex RRDs with inferior breaks, noting 80.1% reattachment but 16.7% oil dispersion.
This meta-analysis evaluated the use of heavy silicone oil (HSO), specifically Densiron 68 and Densiron XTRA, in eyes with rhegmatogenous retinal detachments (RRDs) and inferior retinal breaks. The analysis included 970 eyes and focused on anatomical reattachment rates as the primary outcome, with secondary outcomes including intraocular inflammation, oil dispersion, emulsification, and migration into the anterior chamber.
The pooled findings indicate that anatomical retinal reattachment following endotamponade removal was achieved in 80.1% of cases. However, the analysis also reported notable complication rates: oil dispersion and emulsification occurred in 16.7% of eyes, intraocular inflammation in 13.0%, and oil migration into the anterior chamber in 7.1%. These rates are described as lower than those seen with earlier heavy silicone oil formulations.
The authors acknowledge that despite these promising results, the usage of heavy silicone oil remains limited, particularly in the United States. They suggest that Densiron 68 and Densiron XTRA may be promising tools for managing complex primary and secondary RRDs, but the restricted availability and adoption are important considerations.
Clinicians should interpret these findings cautiously, as the meta-analysis did not report follow-up duration, comparator groups, or statistical measures such as confidence intervals. The absence of these details limits the ability to assess the strength of the evidence and to compare HSO directly with other tamponade options. Nonetheless, for complex RRDs with inferior breaks, heavy silicone oil appears to offer a reasonable anatomical success rate, albeit with a notable risk of oil-related complications.
How this fits prior evidence
This meta-analysis extends prior coverage on rhegmatogenous retinal detachment management by focusing on a specific high-risk subgroup: detachments with inferior retinal breaks. It complements earlier findings on post-repair macular perfusion changes and BCVA improvements, and adds to the discussion of adjunctive therapies for complex detachments. The 80.1% reattachment rate and complication rates provide quantitative context for considering heavy silicone oil as an option, though the limited U.S. usage and lack of comparative data temper its applicability.
Researchers looked at how heavy silicone oil, specifically Densiron 68 and Densiron XTRA, works for patients with a specific type of retinal detachment. The study looked at 970 eyes to see how well the oil helped the retina stay in place and what side effects occurred during treatment.
The results showed that about 80.1% of cases achieved successful anatomical reattachment after the oil was removed. While the oil was effective, some complications did occur. These included a 16.7% rate of oil dispersion and emulsification, a 13.0% rate of intraocular inflammation, and a 7.1% rate of oil moving into the front of the eye.
These specific types of heavy silicone oil are considered promising tools for managing complex cases. They appear to have lower complication rates than older versions of the treatment. However, it is important to note that the use of these specific oils is still limited in some regions, including the United States.
What this means for you:
Heavy silicone oil shows high reattachment rates for certain retinal detachments with lower complication rates than older oils.
Common questions
How effective is heavy silicone oil for retinal detachment?
The study of 970 eyes found that 80.1% of cases achieved anatomical reattachment after the silicone oil was removed. These specific heavy oils are considered promising tools for managing complex cases of retinal detachment.
What are the risks of using heavy silicone oil?
Some risks include oil dispersion or emulsification at a rate of 16.7%, intraocular inflammation in 13.0% of cases, and oil migration into the anterior chamber in 7.1% of cases. These rates are lower than those seen with older formulations.
Is this treatment available to everyone?
While these heavy silicone oils are promising for complex cases, their use remains limited in some areas, particularly in the United States. You should speak with your doctor to see if this specific treatment is an option for your condition.
Rhegmatogenous retinal detachments (RRDs) with inferior retinal breaks (IRBs) pose significant surgical challenges, lacking a universally accepted treatment standard. Heavy silicone oils (HSOs), specifically Densiron® 68 and Densiron XTRA, have emerged as promising endotamponade agents because of their specific gravity, which is greater than that of water, allowing effective tamponade in the inferior retina. Unlike earlier HSO formulations, these newer variants show reduced rates of intraocular inflammation while maintaining favorable anatomical outcomes, even when compared with concomitant scleral buckle use; however, their usage remains limited, particularly in the U.S. We assessed clinical indications, anatomical reattachment rates, and intraocular inflammation linked to Densiron 68 and Densiron XTRA. A comprehensive search of Ovid MEDLINE, EMBASE, and Cochrane CENTRAL identified 616 references, of which 22 studies involving 970 eyes met the inclusion criteria. Pooled analyses revealed a 16.7 % rate of oil dispersion and emulsification, 13.0 % incidence of intraocular inflammation, and 7.1 % occurrence of oil migration into the anterior chamber. Notably, anatomical retinal reattachment following endotamponade removal was achieved in 80.1 % of cases. These findings underscore the efficacy of Densiron 68 and Densiron XTRA in managing complex primary and secondary RRDs, offering a potentially viable solution with lower complication rates than prior HSOs. Their demonstrated success in achieving high anatomical reattachment rates positions them as promising tools in advancing RRD treatment.
